CEO insider buys 113,185 Cosmos Health shares, boosting confidence amid a PathMuscle partnership—yet investors weigh volatility, debt, and biotech risks.
Cosmos Health CEO’s insider buy signals confidence amid debt‑to‑equity conversion and new Libytec partnership—watch how this shapes the company’s future.